CVRx Inc. in Plymouth, Minn. said Monday that hypertension patients using its Rheos stimulation device reported a sharp drop in blood pressure after four years. In a study presented to the European Society of Hypertension meeting, the company said patients’ average systolic blood pressure dropped 27 percent to 140 mmHg (millimeters of mercury) from 193 […]
Updated 6:47 p.m. Small molecule discovery and development company Akebia Therapeutics Inc. reported positive results from a second Phase 1 clinical trial of its anemia drug, as well as the second closing of a $16 million financing round announced almost a year ago, boosting the round to $17 million. Startup Akebia is racing to the […]
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
The company stated it raised additional money to ensure the development of two of its drugs. Akebia plans later this year to start Phase I clinical trials on an oral medication designed to create new red blood cells in anemia patients. In addition, it wants to establish a human clinical proof of concept for a second drug that prevents vascular leak syndrome, in which blood components leak out of veins and into other systems -- a side effect of some cancer treatments.